Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature

Lucie Duval; Sarah Habes; Thierry Chatellier; Pascale Guerzider; Céline Bossard; Claude Masliah; Isabelle Archambeaud; Yann Touchefeu; Tamara Matysiak-Budnik

doi:10.1002/ccr3.2342

Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature

Clin Case Rep. 2019 Jul 28;7(9):1689-1693. doi: 10.1002/ccr3.2342. eCollection 2019 Sep.

Authors

Lucie Duval¹, Sarah Habes^{1

2}, Thierry Chatellier³, Pascale Guerzider⁴, Céline Bossard⁵, Claude Masliah³, Isabelle Archambeaud¹, Yann Touchefeu^{1

6}, Tamara Matysiak-Budnik^{1

2

6}

Affiliations

¹ IMAD, Hepato-Gastroenterology & Digestive Oncology Hôtel Dieu, CHU de Nantes Nantes France.
² University of Nantes Nantes France.
³ Clinic of Estuaire Saint Nazaire France.
⁴ Department of Pathology Hospital of Saint Nazaire Saint Nazaire France.
⁵ Department of Pathology University Hospital of Nantes Nantes France.
⁶ INSERMU1235, TENS University Bretagne Loire Nantes France.

Abstract

Nivolumab may induce severe celiac-like enteropathy, that may appear very rapidly, after only two injections of nivolumab, and may be successfully treated with corticosteroids. This observation underlines the importance of histological analysis of duodenal biopsies and the necessity to rule out a real celiac disease in patients with nivolumab-induced diarrhea.

Keywords: PD‐1 inhibitors; celiac‐like enteropathy; immune‐related adverse effects; immunotherapy; nivolumab.

Publication types

Case Reports